Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National Advertising Division In Brief

This article was originally published in The Tan Sheet

Executive Summary

NAD scrutinizes Colostrum-LD claims

You may also be interested in...



Burner Balm clinical results unveiled

Pacific Shore Holdings' lip balm infused with dietary supplement ingredients for weight management "performed better than anyone expected," says David Toomey, lead investigator in a 12-week, double-blind, placebo-controlled clinical trial involving more than 100 subjects. Los Angeles-based Pacific Shore noted participants using Burner Balm lost an average of seven to nine pounds, many reporting consumption of smaller meals and elimination of snacks. The firm claims the balm's energy-boosting green tea, appetite-suppressing hoodia gordonii, chromium picolinate and caffeine absorb "faster and steadier into the bloodstream" by traveling through blood vessels in the lips. Launching soon to retailers worldwide, Burner Balm sticks are available online at $5.99 apiece

QUOTED. 28 January 2020. Steven Falowski.

Abbott is encouraged by results from two studies of its Proclaim XR neurostimulation system for chronic pain, presented at the annual North American Neuromodulation Society (NANS) meeting in Las Vegas. See what Steven Falowski of Neurosurgical Associates of Lancester in Pennsylvania said about it here.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Topics

UsernamePublicRestriction

Register

PS104727

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel